CompletedNot applicableNCT03109626
Docosahexaenoic Acid (DHA) Replacement for Treatment in Spinocerebellar Ataxia 38
Studying Spinocerebellar ataxia type 38
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Barbara Borroni
- Principal Investigator
- Barbara Borroni, MDAO Spedali Civili
- Intervention
- DHA(dietary_supplement)
- Enrollment
- 10 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2018
Study locations (1)
- AO Spedali Civili, Brescia, BS, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03109626 on ClinicalTrials.gov